Product image of Granitron (Granisetron Hydrochloride) supplied by GNH India

Granitron

Active Ingredient:
Granisetron Hydrochloride
Origin:
EU

Granitron (Granisetron Hydrochloride)

Granitron is a prescription medication that contains the active ingredient granisetron hydrochloride. It is supplied in an oral dosage form, with the specific strength not disclosed in the available data. Granisetron belongs to the 5‑HT3 receptor antagonist class and is used primarily as an antiemetic to help prevent nausea and vomiting associated with chemotherapy and postoperative settings. The product is marketed within the European Union and requires a physician’s prescription.

Manufacturer / TM Owner

Verisfield S.M.S.A

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Granitron is indicated for the prevention of nausea and vomiting in specific clinical situations.

  • Prevention of chemotherapy‑induced nausea and vomiting (CINV) in adult patients.
  • Prevention of postoperative nausea and vomiting (PONV) following surgical procedures.
  • Adjunct therapy for patients receiving highly emetogenic chemotherapy regimens.
  • Use in combination with other antiemetic agents when single‑drug therapy is insufficient.

Side Effects

The safety profile of Granitron includes both frequently observed and less common adverse reactions.

Common

  • Headache.
  • Constipation.
  • Diarrhea.
  • Fatigue.

Serious

  • Severe allergic reaction such as anaphylaxis or angioedema.
  • Cardiac arrhythmia, including rare QT‑interval prolongation.
  • Serotonin syndrome when combined with other serotonergic agents.

Precautions & Warnings

Before initiating Granitron, healthcare providers should consider several precautionary factors.

  • Assess patient history for hypersensitivity to granisetron or other 5‑HT3 antagonists.
  • Use cautiously in patients with known prolonged QT interval or cardiac conduction disorders.
  • Evaluate renal or hepatic impairment, as dose adjustments may be required.
  • Monitor for signs of constipation or bowel obstruction, especially in postoperative patients.
  • Discuss pregnancy and breastfeeding status; safety data are limited.
  • Review concomitant use of other antiemetics to avoid overlapping toxicity.

Avoid Interactions

Granitron may interact with other medications, influencing its efficacy or safety.

Avoid

  • Other 5‑HT3 receptor antagonists (e.g., ondansetron) due to additive antiemetic effect.
  • Drugs known to prolong QT interval (e.g., certain antiarrhythmics, fluoroquinolones).
  • Monoamine oxidase inhibitors (MAOIs) when combined with serotonergic agents.

Use with caution

  • Serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs) or tramadol.
  • Anticholinergic medications that may increase risk of constipation.
  • CYP3A4 inhibitors or inducers, although granisetron is minimally metabolized, monitoring is advised.

Frequently Asked Questions

Granitron contains granisetron hydrochloride, which selectively blocks serotonin 5‑HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, reducing the stimulus for nausea and vomiting.

Both Granitron and ondansetron are 5‑HT3 receptor antagonists, but they may differ in pharmacokinetic properties, dosing schedules, and specific regulatory approvals in various regions.

Granitron is commonly prescribed to prevent nausea and vomiting caused by chemotherapy and to reduce postoperative nausea and vomiting after surgical procedures.

The available information does not specify pediatric dosing; use in children should be guided by a qualified healthcare professional and local prescribing guidelines.

Common adverse effects include headache, constipation, diarrhea, and fatigue, which are generally mild to moderate in intensity.

A known hypersensitivity to granisetron or other 5‑HT3 antagonists is a contraindication. Caution is advised in patients with significant cardiac conduction abnormalities.

Granitron is usually administered orally before the start of chemotherapy, following the timing recommendations provided by the prescribing clinician.

Avoid concurrent use with other 5‑HT3 antagonists, medications that prolong the QT interval, and monoamine oxidase inhibitors. Use serotonergic drugs with caution.

Safety data for Granitron in pregnancy and lactation are limited; clinicians should weigh potential benefits against risks before prescribing to pregnant or nursing individuals.

Renal or hepatic dysfunction may require dose adjustment or closer monitoring, as drug clearance can be altered in these conditions.

Monitoring may include assessment for cardiac rhythm changes, especially QT interval, evaluation of gastrointestinal function, and observation for any signs of allergic reaction.

Combination therapy with antiemetics of different classes may be employed when single‑agent control is insufficient, but clinicians should consider additive side‑effect profiles.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Granisetron Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT